Oxford Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Oxford Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-8,962	Closed	-$572K	–	747
2025 Q1	$572K	Buy	+8,962	New	+$943K	0.26%	106
2024 Q3	–	Sell	-1,865	Closed	-$295K	–	438
2024 Q2	$295K	Buy	+1,865	New	+$240K	0.29%	134
2016 Q2	–	Sell	-187,149	Closed	-$3.65M	–	870
2016 Q1	$3.65M	Buy	187,149 +84,883	+83%	+$1.48M	0.1%	246
2015 Q4	$4.03M	Sell	102,266 -319,708	-76%	-$10.4M	0.1%	233
2015 Q3	$13.6M	Buy	421,974 +319,282	+311%	+$10.8M	0.43%	35
2015 Q2	$3.13M	Buy	+102,692	New	+$2.1M	0.08%	258
2014 Q2	–	Sell	-68,025	Closed	-$1.64M	–	770
2014 Q1	$1.64M	Sell	68,025 -42,053	-38%	-$1.07M	0.05%	399
2013 Q4	$2.24M	Sell	110,078 -430,389	-80%	-$12.8M	0.06%	397
2013 Q3	$25.5M	Buy	540,467 +252,057	+87%	+$9.71M	0.57%	13
2013 Q2	$11M	Buy	+288,410	New	+$10.3M	0.3%	71

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Oxford Asset Management's SRPT Position: Q2 2025 in Review

Oxford Asset Management sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 8,962 shares — an estimated $572K sold.

Oxford Asset Management first reported a position in SRPT in Q2 2013 and held it in 10 quarters. The position peaked at $25.5M in Q3 2013. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

Oxford Asset Management reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
Oxford Asset Management sold 8,962 Sarepta Therapeutics shares in Q2 2025, an estimated $572K.
Oxford Asset Management first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 10 quarters.
Oxford Asset Management's Sarepta Therapeutics position peaked at $25.5M in Q3 2013.
362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on Oxford Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.